Sugammadex 16 mg/kg

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

HypersensitivityReversal of Neuromuscular Blockade

Phase 1

Sugammadex Hypersensitivity Study (Study P06042)

CompletedNCT00988065

Merck Sharp & Dohme LLCHypersensitivity

Start: 2009-09-06End: 2010-04-13Updated: 2019-01-30

Phase 4

Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)

CompletedNCT03346057

Merck Sharp & Dohme LLCReversal of Neuromuscular Blockade

Start: 2017-12-20End: 2019-09-04Updated: 2020-10-08

Related Papers

A randomized trial evaluating the safety profile of sugammadex in high surgical risk ASA physical class 3 or 4 participants

BMC Anesthesiology2021-10-2814 citations

Sugammadex hypersensitivity and underlying mechanisms: a randomised study of healthy non-anaesthetised volunteers.

2018-07-1339 citations